Fosun Pharma announces 2025 A-share stock option incentive plan

Shanghai Fosun Pharmaceutical Group (SSE:600196) has announced its 2025 A-share stock option incentive plan, following approval from its board's remuneration and assessment committee on August 22, 2025. The committee's verification opinion, dated September 29, 2025, confirmed the eligibility of the initial grantees after a ten-day public review period from August 26 to September 4, 2025, during which no objections were raised.

The plan involves granting up to 5,726,100 A-share stock options, representing 0.2144% of the company's total share capital as of August 22, 2025. The initial grant covers 4,580,900 options, and a reserve portion accounts for 1,145,200 options. The exercise price for the initial grant is set at RMB 27.93 per share. The plan includes detailed vesting periods and performance targets based on "net profit attributable to the parent company" and "innovative drug revenue."

Shareholders are invited to an Extraordinary General Meeting on October 23, 2025, to vote on the A-share incentive plan and a related H-share restricted share unit plan. Additionally, the meeting will address the renewal of financial services agreements with Shanghai Fosun High-Tech Group Finance Co., Ltd., and product/service supply framework agreements with Sinopharm Holding Co., Ltd.